Zevra Therapeutics, Inc. (ZVRA) SEC Filings & Earnings Calls

European regulatory setback for arimoclomol

“In July 2026, we announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) adopted a negative opinion regarding the MAA.” · word for word

OLPRUVA commercial underperformance

“We have made the decision to scale back our sales and marketing efforts for OLPRUVA as we evaluate the path forward and weigh strategic alternatives.” · word for word

Dependence on MIPLYFFA for revenue growth

“The increase was primarily attributable to an increase in revenues under the global EAP of $6.4 million and an increase in product sales of MIPLYFFA of $8.7 million.” · word for word

Dependence on MIPLYFFA for rare disease NPC; regulatory risk in EU.

“EU re-examination of Marketing Authorisation Application for arimoclomol.”

Dependence on MIPLYFFA for revenue; any regulatory or commercial setback could materially impact financials.

“MIPLYFFA net revenue $24.6M out of total $36.2M; 68% of total revenue.”

Pipeline risk: Phase 3 DiSCOVER trial for vEDS has only 2 confirmed events out of 62 patients; event-driven trial may take time to read out.

“Enrolled 10 patients in the event-driven Phase 3 DiSCOVER trial... total of two confirmed events.” · word for word

EU regulatory risk: MAA for arimoclomol under EMA review; any negative outcome could limit international expansion.

“A Marketing Authorisation Application for the evaluation of arimoclomol for the treatment of NPC is under review by the European Medicines Agency.” · word for word

OLPRUVA commercial failure

“We have had limited success in commercializing OLPRUVA in the United States, and we are currently evaluating the path forward and weighing strategic alternatives.” · word for word

Dependence on MIPLYFFA for revenue growth

“The increase was primarily attributable to an increase in revenues under the global EAP of $7.9 million and an increase in product sales of MIPLYFFA of $7.5 million.” · word for word

Regulatory risk for European approval

“We are pursuing regulatory approval of arimoclomol in Europe and filed a Marketing Authorization Application ('MAA') with the European Medicines Agency ('EMA') in July 2025; the application is currently under review.” · word for word

OLPRUVA investment scaled back

“During the year, we made the difficult decision to scale back promotional investment for OLPRUVA, reflecting our focus on directing resources toward programs with the greatest long‑term impact.” · word for word

Concentration risk on MIPLYFFA

“$87.4 million from MIPLYFFA (82% of total revenue)”

Loss of SDX portfolio revenue stream; reliance on remaining rare disease pipeline.

“sale of Zevra’s serdexmethylphenidate (SDX) portfolio, including AZSTARYS® and KP1077”

Execution risk on remaining pipeline and commercialization.

“commercial-stage company with a late-stage pipeline” · word for word

Dependence on MIPLYFFA for revenue growth

“The increase was primarily attributable to an increase in product sales of MIPLYFFA of $77.3 million” · word for word

Inventory obsolescence for OLPRUVA

“$11.7 million in inventory obsolescence reserve expense related to OLPRUVA inventory during the year ended December 31, 2025.” · word for word

Significant intangible asset impairment

“Impairment of intangible assets 58,710 — 58,710” · word for word

Reliance on single specialty pharmacy customer

“Our current single customer for product sales of MIPLYFFA and OLPRUVA is a specialty pharmacy provider.” · word for word

Clinical trial risk for DiSCOVER trial; regulatory risk for EU MAA

“Phase 3 DiSCOVER trial ongoing; EMA review with 120-day questions”

Minimal risk; routine board change with experienced appointee.

“No disagreement; new director has extensive life sciences experience.”

CFO transition risk; potential disruption to financial operations.

“CFO resigning effective Dec 31, 2025; search for successor initiated.”

OLPRUVA commercial underperformance; sales and marketing efforts scaled back.

“OLPRUVA: One prescription enrollment form during Q3 2025... the Company has decided to scale back its sales and marketing efforts for OLPRUVA.” · word for word

Reliance on MIPLYFFA for revenue; single product dependency.

“Q3 2025 net revenue of $26.1 million, driven by MIPLYFFA net revenue of $22.4 million.” · word for word

OLPRUVA commercial failure

“We recorded an intangible asset impairment charge of $58.7 million in the unaudited condensed consolidated statement of operations for the nine months ended September 30, 2025.” · word for word

Dependence on MIPLYFFA for revenue

“The increase was primarily due to an increase in product sales of MIPLYFFA of $22.4 million.” · word for word

Clinical trial risk for celiprolol

“Recruitment in the Phase-3 trial was restarted mid-2024, and the trial has 44 enrolled participants as of September 30, 2025.” · word for word

Debt covenant risk

“The Credit Agreement contains customary affirmative and negative covenants... must maintain a minimum cash balance of $20.0 million” · word for word